Natera, Inc.

Natera is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera advances molecular diagnostics with integrity and scientific rigor, and supports integration of information provided by our tests into health care decision making. Our tests are clinically validated in over 100 peer-reviewed publications with over 1.3 million patients studied. We participated in the largest prospective studies to date in molecular diagnostics in oncology (CIRCULATE), women’s health (SMART), and organ health (Trifecta). We meet or exceed applicable industry and regulatory standards for all of our tests to deliver high-quality results, and have processed over 5 million tests in our CAP/CLIA‑certified labs.